Bluejay Diagnostics Corp - צמיחת מכירות משנה לשנה (TTM) BJDX

Bluejay Diagnostics (BJDX) is developing the Symphony platform for instantaneous blood analysis in intensive care units. The company accumulates its primary capital through the sale of portable devices and disposable cartridges for rapid diagnostics. A narrow specialization in sepsis creates binary risks, which the year-over-year product sales dynamics for TTM confirm, as the indicator remains at 0.00.

For Bluejay Diagnostics (BJDX), the expansion of Symphony systems into intensive care units correlates directly with revenue dynamics, confirming market dominance in the rapid sepsis diagnostics niche. By analyzing the TTM sales growth, an investor can observe the percentage change in revenue over a rolling year, which neutralizes seasonality and quarterly distortions, allowing for an assessment of the business's fundamental resilience to macroeconomic shocks.